RecommendMail Facebook Twitter Google Plus

Jenoptik achieves breakthrough in the high-tech pharma-facilities business

Clean Systems Technologies business division is planning the world's largest insulin plant for the pharma-partners Hoechst Marion Roussel and Pfizer in Frankfurt.

A 50:50 joint venture of the Jenoptik subsidiary M+W Zander has received a large-scale order to plan the world's greatest plant for insulin production. The order by Hoechst Marion Roussel (HMR) and Pfizer, two pharma-manufacturers, envisages contract work to be performed by Life Sciences-Meissner+Wurst GmbH (LSMW) in Stuttgart in planning their new joint pharmaceutical factory in the industry park Frankfurt-Hoechst, where inhalable insulin will be produced for the first time ever. According to a statement of HMR and Pfizer, this remedy is a new milestone in the treatment of diabetes. Requested engineering services correspond to a value in the double-digit million marks range.

"With this order, we have achieved a breakthrough in the pharma-industry" said Lothar Späth, Chairman of the Executive Board of JENOPTIK AG. As was officially stated by Jenoptik's chief representative, the strategy for expanding Clean Systems Technologies operations has been aimed since 1995 at establishing a fast-growing stronghold in the biotechnology and pharmaceuticals market in addition to business with the electronics industry.

The founding of LSMW three years ago marked the first milestone in this strategy. A decisive impetus to the expansion efforts was derived in 1998, when the Jenoptik subsidiary M+W merged with the Nuremberg-based Zander-Group which had already been strongly involved in the pharma-business.

"For the JENOPTIK Group, the project is as significant as the first large order by the semiconductor industry which we received from Philips, Eindhoven, in 1983" says Jürgen Giessmann, who is chairman of M+W Zander and member of the board of JENOPTIK AG. The concept of the two Jenoptik companies has prevailed over those of twelve international competitors to win the award for this large project by HMR and Pfizer.

Investor Relations


+49 3641 65-2120

+49 3641 65-2804